Articles by Jill Wechsler - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jill Wechsler

Commentary: Healthcare Reform is Ruled Constitutional

What's next for biotech?
Jun 29, 2012

In a 5–4 vote, the Supreme Court has ruled in favor of the Constitutionality of the Affordable Care Act.

Interview with FDA: Adopting New Strategies to Oversee Global Economy

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.
Jun 1, 2012

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.

FDA Explores Options to Expand Access to NonPrescription Drugs

Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.
May 1, 2012

Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.

Manufacturers Wrestle with Drug Abuse and Critical Shortages

Soaring opioid use creates challenges for new drug development and supply-chain control.
Apr 1, 2012

Soaring opioid use creates challenges for new drug development and supply-chain control.

Communications Advances Present Challenges to Manufacturers

Social media use raises questions about applying old standards to new information technology.
Mar 1, 2012

Social media use raises questions about applying old standards to new information technology.

FDA Unveils Guidance for Biosimilar Development

Feb 14, 2012

After months of anticipation, FDA issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies.

FDA and Justice Department Address Drug Quality Concerns

More collaboration and expanded oversight aim to compel manufacturers to follow GMPs.
Feb 1, 2012

More collaboration and expanded oversight aim to compel manufacturers to follow GMPs.

Budget Crunch, Political Battles Shape Policy Agenda for Year

Pressure to approve new user fees opens the door to action on drug shortages, prices, and regulation.
Jan 1, 2012

Pressure to approve new user fees opens the door to action on drug shortages, prices, and regulation.

FDA Revamps to Meet New Challenges

Added responsibilities and outside concerns prompt overhaul of agency's structure.
Dec 1, 2011

Added responsibilities and outside concerns prompt overhaul of agency's structure.

ADVERTISEMENT

ADVERTISEMENT

Click here